A total of 813 patients diagnosed with stage III hepatocellular carcinoma between 2010 and 2013 were included in the modeling group, including 661 males, 152 females; 141 cases aged 18–53 years, 583 cases aged 54–74 years, 89 cases age ≥ 75 years; 680 cases were AFP positive, 133 cases were AFP negative and 664 cases had severe liver fibrosis. This evidence concerns the gene AFP and hepatocellular carcinoma.